Intravenous Alteplase in Ischemic Stroke Patients not Fully Adhering to the Current Drug License in Central and Eastern Europe
- 7 February 2012
- journal article
- research article
- Published by SAGE Publications in International Journal of Stroke
- Vol. 7 (8) , 615-622
Abstract
Background: The current European license for alteplase in acute ischemic stroke excludes from treatment large groups of patients. Nevertheless, in everyday practice, many patients receive off-label thrombolysis at the physician's discretion. Aim: Our aim was to evaluate safety and effectiveness of intravenous alteplase in patients not fully adhering to the drug license compared with those treated strictly according to the license in Central and Eastern Europe. Methods: We analyzed the data contributed to Safe Implementation of Thrombolysis in Stroke registry from nine countries between February 2003 and February 2010. Statistical analysis included multivariate logistic regression. Results: Of 5594 consecutive patients, 1919 patients (34·3%) not fully adhered to the license. The most frequent deviations were: time-to-treatment >3 h (13·1%), use of intravenous antihypertensives (8·3%), age >80 years (7·3%), oral anticoagulation (4·2%), a previous stroke with concomitant diabetes (3·9%), and previous stroke 3 h was an independent predictor of unfavorable outcome (odds ratio 1·32; 95% confidence interval: 1·01–1·71). Conclusion: Our findings show that patients not fully adhering to the European license are not at increased risk of symptomatic intracranial haemorrhage but achieve less favorable outcome. Some contraindications appear more redundant than others. However, the final conclusions about safety and effectiveness should be based on the results of ongoing randomized trials.Keywords
This publication has 24 references indexed in Scilit:
- Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials ArchiveBMJ, 2010
- Intravenous Alteplase for Stroke in Those Older Than 80 Years OldStroke, 2010
- Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trialsThe Lancet, 2010
- Hospital Rates of Thrombolysis for Acute Ischemic StrokeStroke, 2009
- A nationwide study on topography and efficacy of the stroke treatment network in the Czech republicJournal of Neurology, 2009
- Is it Time to Reassess the SITS-MOST Criteria for Thrombolysis?Stroke, 2009
- Thrombolysis with alteplase 3–4·5 h after acute ischaemic stroke (SITS-ISTR): an observational studyThe Lancet, 2008
- Determinants of outcome and safety of intravenous rt-PA therapy in the very old: a clinical registry study and systematic reviewAge and Ageing, 2007
- Intravenous Alteplase for StrokeStroke, 2007
- Intravenous thrombolysis in stroke patients of ≥80 versus <80 years of age—a systematic review across cohort studiesAge and Ageing, 2006